|
280. Liang, S. H. “From Lutetium to Terbium: A New Era in PSMA-Targeted Radioligand Therapy for mCRPC Patients”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 219–222.
|
|
279. Liang, S. H. “PARP-Targeted Molecular Imaging for Noninvasive Diagnosis and Surgical Guidance in Basal Cell Carcinoma”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 208–211.
|
|
278. Shi, H.; Li, Y. and Liang, S. H. “Selective 7-Azaindole Modulators Targeting Fyn and GSK-3β for Dual-Target Neuromodulation”, ACS Medicinal Chemistry Letters,
|
|
277. Wu, R.; Rong, J.; Hou, Y.; Yin, C.; Zhou, Y.; Gai, Y.; Haider, A.; Lan, X.; Liang, S. H.; Gao, Z. and Xia, X. “S1PR-Targeted PET Imaging: Advancing Insights into Neuroinflammatory and Immune-Related Pathologies”, Molecular Pharmaceutics, 2025, ASAP. Link: https://pubmed.ncbi.nlm.nih.gov/41397090/
|
|
276. Li, Y.; Mori, W.; Song, Z.; Yamasaki, T.; Zhao, T.; Chen, J.; Zhang, Y.; Zhou, X.; Xie, L.; Kokufuta, T.; Hu, K.; Hu, Q.-L.; Fujinaga, M.; Li, X.; Kumata, K.; Li, C.; Sun, Z.; Gao, Y.; Hoyle, D.; Patel, J.; Yuan, H.; Zhang, M.-R. and Liang, S. H. “Radiosynthesis and Preclinical Evaluation of a Novel 11C-labeled Pyrazolopyrimidine Derivatives for Positron Emission Tomography Imaging of Phosphodiesterase 2A”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00649
|
|
275. Sabnis, R. W.; Liang, S. H.; Abdel-Magid, A. F.; Rosse, G. and Kargbo, R. B. “Patent Highlights at the Frontier of Neuroscience: From Molecular Targets to Psychedelic Neurotherapeutics”, ACS Medicinal Chemistry Letters, 2025, ASAP. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00699
|
|
274. Tay, D.; Ahmed, H.; Dawoud, A.; Salam, M.; Gobbi, L.; Grether, U.; Edelmann, M. R.; Wittwer, M. B.; Collin, L.; Atz, K.; Keaney, J.; Giroud, M.; Rossi, A.; Gennari, A. G.; Pagano, G.; Parrot, N. J.; Barakovic, M.; Rominger, A.; Gebhard, C.; Ametamey, S. M.; Saindane, A. M.; Liang, S. H. and Haider, A. “Translational molecular imaging and drug development in multiple sclerosis”, Theranostics, 2026, 16, 1630–1657. Link: https://www.thno.org/v16p1630.htm.
|
|
273. Zhou, X.; Patel, J. S.; Zhao, T. and Liang, S. H. “The Promise of Selective PARP1 Inhibitors in Cancer Therapy”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2103–2107. Link: https://pubmed.ncbi.nlm.nih.gov/41256971/
|
|
272. Li, Y.; Wang, L.; Pei, Z.; Factor, S. A. and Liang, S. H. “Isoindolinone-Derived PET Tracers for Molecular Imaging of mHTT Aggregates in Huntington’s Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2097–2102. Link: https://pubmed.ncbi.nlm.nih.gov/41257000/
|
|
271. Zhao, T.; Patel, J. S.; Ran, C. and Liang, S. H. “Advances in PET imaging of oxidative stress: tracer innovation, mechanistic insight, and translational potential”, European Journal of Nuclear Medicine and Molecular Imaging, 2025, Online ahead of print. Link: https://pubmed.ncbi.nlm.nih.gov/40956410/
|
|
270. Patel, J. S.; Li, R. and Liang S. H. “Visualizing T-cell activation: PET imaging of CXCL9 as a window into the tumor immune response”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 5, 212–214. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12629901/
|
|
269. Banke, T. G.; Regan, M. C.; Perszyk, R. E.; Zhang, L.; Xing, H.; Chen, J.; Won, S.; Simorowski, N.; Diaz, E. S.; Kim, S.; Song, R.; Rong, J.; Zhou, X.; Chaudhary, A. F.; Zhang, J.; Traynelis, J. F.; McDaniels, E. D.; Nitsche, K.; Roache, S.; Raymond, C. S.; Low, C.-M.; Myers, S. J.; Roche, K. W.; Liang, S. H.; Traynelis, S. F.; Furukawa, H. and Yuan, H. “Inhibition of GluN2B-containing N-methyl-d-aspartate receptors by radiprodil”, Brain, 2025, Online ahead of print. Link: https://doi.org/10.1093/brain/awaf355
|
|
268. Zhang, J.-J.; Yang, J.; Patel, J. S.; Lv, R.; Zhang, Z.; Ji, X.; Tang, L.; Chen, Z. and Liang, S. H. “Emerging Molecular PET Imaging for Cell Death in Neurodegenerative Diseases”, Journal of Medicinal Chemistry, 2025, 68, 21, 22033–22046. Link: https://pubmed.ncbi.nlm.nih.gov/41150964/
|
|
267. Zhao, T.; Haider, A. and Liang, S. H. “18F-Flurpiridaz PET for Imaging of Myocardial Ischemia”, Trends in Pharmacological Sciences, 2025, 46, 11, 1146-1147. Link: https://pubmed.ncbi.nlm.nih.gov/40813202/
|
|
266. Liang, S. H. “Development of Novel PET Tracers for Imaging Non-AD Tauopathies”, ACS Medicinal Chemistry Letters, 2025, 16, 10, 1884-1888. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00487
|
|
265. Liang, S. H. “Chelator Optimization and Therapeutic Potential of 188Re-FAPI for FAP-Targeted Radionuclide Therapy”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1697–1702. Link: https://doi.org/10.1021/acsmedchemlett.5c00486
|
|
264. Haider, A.; Xiao, Z.; Chen, J.; Pfister, S. K.; Zhou, X.; Li, Y.; Chaudhary, A.; Zhao, C.; Rong, J.; Paehler, A.; Mohr, S.; Norcross, R. D.; Honer, M.; Mu, L.; Gobbi, L.; Schibli, R.; Hoener, M. C. and Liang, S. H. “Preclinical Development of [18F]TAAR1-2203 as a PET Radioligand for Imaging TAAR1 Expression and Receptor Occupancy”, European Journal of Nuclear Medicine and Molecular Imaging, 2025.
|
|
263. Zhou, X. and Liang, S. H. “Development of Selective PARP1 Inhibitors for Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025, 16, 10, 1914–1917. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00536 |
|
262. Zhou, X.and Liang, S. H. “Development of Novel Compounds and Methods for Treatment of PARPs Mediated Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 10, 1910–1913. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00530 |
|
261. Yang, J.; Yang, Y.; Wang, H.; Liang, S. H. and Ran, C. “Molecular Afterglow of Lophine-Based Luminophore and Its Imaging Applications”, Angewandte Chemie International Edition, 2025, e202507174. Link: https://pubmed.ncbi.nlm.nih.gov/40852797/
|
|
260. Xiao, Z.; Sun, J.; Fujinaga, M.; Wei, H.; Zhao, C.; Haider, A.; Van, R.; Kuang, S.; Yamasaki, T.; Zhang, Y.; Rong, J.; Hu, K.; Chen, J.; Leon, E. C.; Mori, W.; Xie, L.; Wei, J.; Xu, Y.; Shao, Y.; Zhang, H.-T.; Xu, Y.; Ran, C.; Lloyd, K. C. K.; Wang, L.; Zhang, M.-R. and Liang, S. H. “Radiosynthesis and Preclinical Evaluation of a Carbon-11 Labeled Phosphodiesterase 7 Inhibitor for PET Neuroimaging”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1835–1843. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00385
|
|
259. Liang, S. H. “Novel N-(Pyridin-3-yl)benzamide Derivatives as Histone Acyl Transferase Positive Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2147–2148. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00554 |
|
258. Liang, S. H. “Novel N-Arylquinoline-4-carboxamide Derivatives as Prostaglandin F Receptor Antagonists”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2149–2151. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00553 |
|
257. Zhou, X. and Liang, S. H. “Synthesis of Novel PARP Inhibitors and Their Uses in Treatment of PARPs Related Diseases”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2152–2153. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00577 |
|
256. Song, Z.; Li, Y.; Dahl, K.; Sun, Z.; Chen, J.; Zhou, X.; Gao, Y.; Rong, J.; Zhao, C.; Yuan, K.; Chaudhary, A. F.; Patel, J. S.; Collier, T. L.; Ran, C.; Muehlfenzl, K. S.; Haider, A.; Elmore, C. S.; Schou, M. and Liang, S. H. “Development and Preclinical Characterization of [18F]H3-2406 and [18F]H3-2407 for Positron Emission Tomography Imaging of the Histamine Subtype-3 Receptor”, Journal of Medicinal Chemistry, 2025, 68, 15, 15372–15385. Link: https://pubmed.ncbi.nlm.nih.gov/40665705/
|
|
255. Li, Y. and Liang, S. H. “Selective Modulation of the GluN2B/C/D Containing N-Methyl-d-Aspartate Receptors: A New Frontier in Targeted Neurotherapeutics”, ACS Medicinal Chemistry Letters, 2025, 16, 7, 1226–1230. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00365
|
|
254. Li, X. and Liang, S. H. “Imidazo Pyrimidine Compounds for the Inhibition of Oncogenic KRAS Mutations in Cancer Therapy”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2194–2196. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00628 |
|
253. Hoyle, D. E. and Liang, S. H. “Design and Synthesis of Novel USP1 Inhibitors for Therapeutic Applications”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2197–2199. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00627 |
|
252. Song, Z. and Liang, S. H. “Novel 2H-Pyrazolo[3,4-d]thiazole Compounds Targeting NLRP3 for the Treatment of Neurodegenerative Diseases”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2200–2201. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00626 |
|
251. Hu, Q-L. and Liang, S. H. “Novel Bicyclic Peptides Targeting Interleukin-23 Receptor to Relieve Inflammatory Conditions”, ACS Medicinal Chemistry Letters, 2025, 16, 11, 2202–2203. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00625 |
|
250. Liang, S. H. “Trop2-Targeted ImmunoPET Ligands”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15(3):105–108.
|
|
249. Zhao, T. and Liang, S. H. “Streamlining First-in-Human PET Radiopharmaceutical Development: FDA’s Evolving Stance on Preclinical Dosimetry”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15(4):171–172.
|
|
248. Rong, J.; Zhao, C.; Chaudhary, A. F.; Chen, J.; Li, Y.; Zhou, X.; Song, Z.; Sun, Z.; Gao, Y.; Feng, S.; Zhao, T.; Hu, Q.-L.; Li, C.; Haider, A.; Patel, J.; Ran, C.; Yuan, H. and Liang, S. H. “Radiosynthesis and Evaluation of an 18F-Labeled Radioligand for Imaging Metabotropic Glutamate Receptor 3 with Positron Emission Tomography”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15(5), 173-182. |
|
247. Rong, J.; Zhao, C.; Chaudhary, A. F.; Chen, J.; Li, Y.; Zhou, X.; Song, Z.; Sun, Z.; Gao, Y.; Feng, S.; Zhao, T.; Hu, Q.-L.; Li, C.; Patel, J. S.; Yuan, H.; Haider, A. and Liang, S. H. “Development of Novel 18F-Labeled Selective Orexin-2 Receptor Radioligands for Positron Emission Tomography”, ACS Pharmacology & Translational Science, 2025, 8, 4070-4079.
|
|
246. Zhao, T. and Liang, S. H. “Novel Tracers and Emerging Targets for Positron Emission Tomography in Alzheimer’s Disease and Related Dementias”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 4, 167–170. Link: https://pubmed.ncbi.nlm.nih.gov/40980740/ |
|
245. Liang, S. H. “DLL3-Targeted ImmunoPET and Radioimmunotherapy Ligands”, American Journal of Nuclear Medicine and Molecular Imaging, 15, 5, 215–218. Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC12629904/
|
|
244. Zhao, T. and Liang, S. H. “Development of Bicyclic Compounds Containing a Tertiary Amine Moiety as T Cell Activators”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1731–1732. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00496 |
|
243. Hu, Q. and Liang, S. H. “Novel Cyclic Peptides Trapping Interleukin-1β to Relieve Inflammatory and Atherosclerotic Cardiovascular Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1733–1735. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00495 |
|
242. Rong, J. and Liang, S. H. “Novel Indazole Propionic Acid Derivatives as AMPK Activators”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1736–1737. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00494 |
|
241. Rong, J. and Liang, S. H. “Novel Pyrido[4,3-d]pyrimidine Compounds as KRAS Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 9, 1738–1739. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00493 |
|
240. Song, Z. and Liang, S. H. “Novel Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors for the Treatment of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1511–1512. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00438 |
|
239. Li, C.; Song, Z.; Hu, Q.; Li, Y.; Patel, J. S. and Liang, S. H. “CD45-targeted PET enables the visualization of inflammatory conditions”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 3, 124–129. Link: https://pubmed.ncbi.nlm.nih.gov/40688532/
|
|
238. Zhou, X. and Liang, S. H. “The Development of Inhibitors for NLRP3 Inflammasome”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1513–1514. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00437 |
|
237. Zhao, T. and Liang, S. H. “Novel Thieno[3,2-b]Pyridine Derivatives in the Treatment of Huntington’s Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1515–1516. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00436 |
|
236. Hu, Q. and Liang, S. H. “Novel Peptides as GIPR/GLP-1R/GCGR Triagonists for Treating Type 2 Diabetes Mellitus”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1517–1519. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00435 |
|
235. Zhou, X. and Liang, S. H. “Preparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1494–1496. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00411 |
|
234. Zhou, X. and Liang, S. H. “Novel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment”, ACS Medicinal Chemistry Letters, 2025, 16, 8, 1497–1498. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00410 |
|
233. Li, Y.; Dahl, K.; Elmore, C. S.; Sandell, J.; Takano, A.; Halldin, C.; Farde, L.; Ahlgren, C.; Cochrane, A.; Rong, J.; Chen, J.; Zhao, C.; Zhou, X.; Patel, J. S.; Song, Z.; Chaudhary, A.; Gao, Y.; Sun, Z.; Zhang, Z.; Feng, S.; Haider, A.; Liang, S. H. and Schou, M. “Radiosynthesis and Evaluation of 11C-Labeled Imidazolyl Pyrimidine Derivatives for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3”, ACS Pharmacology & Translational Science, 2025, 8, 7, 1986–1995.
|
|
232. Li, Y. and Liang, S. H. “Novel Isoindolin-1-one Derivatives as Metabotropic Glutamate Receptor Positive Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 7, 1249–1250. |
|
231. Zhou, X. and Liang, S. H. “Targeted Treatment of Cancer by Using Conjugate Compounds with Poly(ADP-ribose) Polymerase (PARP) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 7, 1254–1255. |
|
230. Zhou, X. and Liang, S. H. “Synthesis of Novel Substituted N-heterocycles and Their Use of Selective Poly(ADP-ribose) Polymerase 1 (PARP1) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, accepted. |
|
229. Liang, S. H. “Novel Heterocyclic 5H-dibenzo[b,f]azepine Derivatives as Selective HDAC6 inhibitors for Treatment of Charcot Marie Tooth Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 7, 1245–1246. |
|
228. Liang, S. H. “Novel (1H-Pyrazol-4-ylamino)pyrimidine Derivatives as Wee1 Inhibitors for Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025, 16, 7, 1247–1248. |
|
227. Ran, W.; Hu, K.; Ye, W.; Zhang, L.; Chen, J.; Ji, B.; Mori, W.; Wang, Z.; Lu, H.; Haider, A.; Yamasaki, T.; Huang, H.; Xie, L.; Yang, Q.; Yuan, S.; Wang, X.; Gong, J.; Wang, H.; Liang, S. H.; Wang, J.; Wang, R.; Zhang, M. R. and Wang, L. “Radiofluorination of 2-Arylquinolin-4-yl Oxypropanamide Derivatives for TSPO Imaging in Neuroinflammatory Murine, Nonhuman Primates, and Human Brain Autoradiography with Insensitivity to the rs6971 Polymorphism”, Journal of Medicinal Chemistry, 2025, 68, 12, 12457–12472. https://pubmed.ncbi.nlm.nih.gov/40489695/
|
|
226. Zhou, X.; Chen, J.; Patel, J. S.; Ran, W.; Li, Y.; Van, R. S.; Ibrahim, M. M. H.; Zhao, C.; Gao, Y.; Rong, J.; Chaudhary, A. F.; Li, G.; Hu, J.; Davenport, A. T.; Daunais, J. B.; Shao, Y.; Ran, C.; Collier, T. L.; Haider, A.; Schuster, D. M.; Levey, A.; Wang, L.; Corfas, G. and Liang, S. H. “Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand”, Acta Pharmaceutica Sinica B, 2025, 15, 10, 5036-5049. https://www.sciencedirect.com/science/article/pii/S2211383525003260
|
|
225. Shao, T.; Gu, Z.; Liu, Y.; Wang, X.; Tang, C.; Chen, N.; Wang, M.; Liu, X.; Song, H.; Chen, S.; Li, W.; Hui, H.; Jia, X.; Mao, H.; Chung, R. T.; Liang, S. H.; Xiong, S. and Tian, J. “Long-term in vivo monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging”, EBioMedicine, 2025, 116, 105775. https://pubmed.ncbi.nlm.nih.gov/40435720/
|
|
224. Song, Z. and Liang, S. H. “Novel Tetrahydrocyclohepteneindole Derivatives Targeting Estrogen Receptor Alpha for the Treatment of Breast Cancer”, ACS Medicinal Chemistry Letters, 2025, 16, 6, 967–969. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00283 |
|
223. Hu, Q-L. and Liang, S. H. “Deuterated 1,3 Dihydro-2H-indole-2-one Derivatives for Treatment of Depression or Anxiety”, ACS Medicinal Chemistry Letters, 2025, 16, 6, 965–966. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00284 |
|
222. Zhou, X. and Liang, S. H. “Synthesis and Application of Novel Arginine Vasopressin Receptor 1A (AVPR1A) Antagonists”, ACS Medicinal Chemistry Letters, 2025, 16, 6, 963–964. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00285 |
|
221. Rong, J. and Liang, S. H. “Novel 2,6,9-Trisubstituted Purines as CDK2 Inhibitors for Treating Cancers”, ACS Medicinal Chemistry Letters, 2025, 16, 6, 970–971. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00282 |
|
220. Liang, J.; Weng, S.; Zhang, J.; Jiang, S.; Li, W.; Li, S.; Rong, J.; Liu, H.; Chen, H.; Liu, Z.; Peng, H.; Yan, S.; Zhang, R.; Liang, S. H. and Zhang, L. “Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI”, European Journal of Nuclear Medicine and Molecular Imaging, 2025, 52, 3951–3962. Link: https://pubmed.ncbi.nlm.nih.gov/40232335/
|
|
219. Dong, C.; Ye, W.; Xu, Y.; Chen, J.; Liao, K.; Wei, H.; Jiang, Y.; Hou, L.; Wei, J.; Tan, Z.; Song, Z.; Li, Y.; Haider, A.; Yuan, H.; Liang, S. H. and Wang, L. “Automatic synthesis of a phosphodiesterase 4B (PDE4B) radioligand and PET imaging in depression rodent models”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 55-64. Link: https://pubmed.ncbi.nlm.nih.gov/40401108/
|
|
218. Feng, S. and Liang, S. H. “Novel Sulfonamide Derivatives as Nav1.5 Sodium Channel Blockers for Treating Atrial Fibrillation”, ACS Medicinal Chemistry Letters, 2025, 16, 748-749. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00192 |
|
217. Song, Z. and Liang, S. H. “Novel Tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine Compounds as Oxytocin Receptor Agonists for Treating Autism Spectrum Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 752-753. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00190 |
|
216. Li, Y. and Liang, S. H. “Novel Nonpeptide as Oxytocin Receptor Agonist”, ACS Medicinal Chemistry Letters, 2025, 16, 750-751. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00191 |
|
215. Li, Y. and Liang, S. H. “Novel Tricyclic Compounds as GSK3 Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 724-727. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00162 |
|
214. Li, Y. and Liang, S. H. “Novel Heterocyclic Pyrimidine Derivatives as GSK3α Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 721-723. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00159 |
|
213. Song, Z. and Liang, S. H. “Novel Azaindole Compounds as Phosphodiesterase 4B Inhibitors for Treating Immune-Inflammatory Diseases or Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 717-718. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00158 |
|
212. Li, Y. and Liang, S. H. “Novel 2-Pyrrolidone Derivatives as Negative Allosteric Modulators of GluN2B-Containing NMDA Receptors”, ACS Medicinal Chemistry Letters, 2025, 16, 719-720. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00157 |
|
211. Li, Y.; Yuan, H. and Liang, S. H. “Advances in the Structural Basis of GluN2A-Selective Negative Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 6, 911–915. https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00226
|
|
210. Zhao, T. and Liang, S. H. “PDE7 as a Precision Target: Bridging Disease Modulation and Potential PET Imaging for Translational Medicine”, ACS Medicinal Chemistry Letters, 2025, 16, 711-714. DOI: 10.1021/acsmedchemlett.5c00160
|
|
209. Li, C.; Hu, Q. and Liang, S. H. “CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 37-43. DOI: 10.62347/VHYY2134. eCollection 2025
|
|
208. Zhao, T. and Liang, S. H. “Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics”, American Journal of Nuclear Medicine and Molecular Imaging, 2025, 15, 82-86. DOI: 10.62347/TUZI7617. eCollection 2025
|
|
207. Zhou, X. and Liang, S. H. “Preparation of Substituted Heterocycles and Their Use as DNA Polymerase Theta (POLQ) Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 536-537. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00137 |
|
206. Zhao, T. and Liang, S. H. “Novel Triazole-Substituted Imidazo[1,2-a]Pyrimidine Compounds as cGAS inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 530-531. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00136 |
|
205. Hu, Q-L. and Liang, S. H. “Novel Cyclic Peptides as Interleukin-23 Inhibitor for Treating Inflammatory Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 532-533. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00135 |
|
204. Rong, J. and Liang, S. H. “Novel Pyrazolo[1,5-a]pyrimidine-3,5-diamines as nSMase2 Inhibitors”, ACS Medicinal Chemistry Letters, 2025, 16, 534-535. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00134 |
|
203. Li, Y. and Liang, S. H. “6-Aryl Isoindolin-1-ones: Novel mGluR2 Negative Allosteric Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 512-513. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00106 |
|
202. Li, Y. and Liang, S. H. “Novel 6-Aryl isoindolin-1-one Derivatives as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 2”, ACS Medicinal Chemistry Letters, 2025, 16, 510-511. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00107 |
|
201. Zhao, T. and Liang, S. H. “Enhancing the Stability of 211At Radiopharmaceuticals: Insights from Ortho-Substituent Strategies”, ACS Medicinal Chemistry Letters, 2025, 16, 504–507. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00102
|
|
200. Bi, C.; Patel, J. S. and Liang, S. H. “Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy”, Journal of Medicinal Chemistry, 2025, 68, 6860–6869. DOI: https://doi.org/10.1021/acs.jmedchem.4c021
|
|
199. Rong, J.; Zhao, C.; Chaudhary, A. F.; Chen, J.; Zhou, X.; Zhang, K.; Song, Z.; Sun, Z.; Gao, Y.; Zhang, Z.; Feng, S.; Collier, T. L.; Yuan, H.; Patel, J. S.; Haider, A.; Li, Y. and Liang, S. H. “Development of a Novel 18F-Labeled Radioligand for Imaging Cholesterol 24-Hydroxylase with Positron Emission Tomography”, ACS Pharmacology & Translational Science, 2025, 8, 800–807. DOI: https://pubs.acs.org/doi/10.1021/acsptsci.4c00683
|
|
198. Rong, J.; Zhao, C.; Chaudhary, A. F.; Jones, E.; Van, R.; Song, Z.; Li, Y.; Chen, J.; Zhou, X.; Patel, J. S.; Gao, Y.; Sun, Z.; Feng, S.; Zhang, Z.; Collier, T. L.; Ran, C.; Haider, A.; Shao, Y.; Yuan, H. and Liang, S. H. “Development of a Novel 18F-Labeled Radioligand for Imaging Phosphodiesterase 7 with Positron Emission Tomography”, Molecular Pharmaceutics, 2025, 22, 1657–1666. DOI: https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.4c01379
|
|
197. Pees, A.; Morrone, C. D.; Tong, J.; Rong, J.; Shao, T.; Wear, D.; Liang, S. H.; Yu, W. H.; Vasdev, N. “Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer’s disease revealed by PET imaging with [18F]FMPEP-d2 and [18F]MAGL-2102”, Theranostics, 2025, 15, 3368-3385. Link: https://www.thno.org/v15p3368.htm
|
|
196. Feng, S. and Liang, S. H. “Identification of Indazole- and Azaindazole-Substituted Cyclopentapyrroles as G2019S Leucine-Rich Repeat Kinase 2 Inhibitors for the Treatment of CNS Disorders”, ACS Medicinal Chemistry Letters, 2025, 16, 368–370. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00045 |
|
195. Rong, J.; Zhao, C.; Chaudhary, A. F.; Ware, T.; Van, R. S.; Li, Y.; Leon, E. R. C.; Dang, V.; Chen, J.; Xiao, Z.; Zhou, X.; Zhang, W.; Bi, C.; Zhang, K.; Patel, J. S.; Shao, Y.; Ran, C.; Collin, L.; Haider, A.; Cravatt, B. F. and Liang, S. H. “Development of a novel 18F-labeled reversiblebinding radioligand for imaging monoacylglycerol lipase with positron emission tomography”, Acta Pharmaceutica Sinica B, 2025, 22, 3, 1657–1666.
|
|
194. Li, Y.; Mori, W.; Chaudhary, A.; Zhao, C.; Yamasaki, T.; Zhang, Z.; Feng, S.; Ware, T.; Rong, J.; Fujinaga, M.; Chen, J.; Kumata, K.; Zhang, Y.; Hu, K.; Xie, L.; Zhou, X.; Song, Z.; Gao, Y.; Sun, Z.; Patel, J. S.; Zhai, C.; Yuan, K. Y.; Collier, T. L.; Ran, C.; Collin, L.; Haider, A.; Grether, U.; Wittwer, M. B.; Cravatt, B. F.; Zhang, M.-R. and Liang, S. H. “Radiosynthesis and Evaluation of Novel 18F Labeled PET Ligands for Imaging Monoacylglycerol Lipase”, European Journal of Medicinal Chemistry, 2025, 285, 117246. Link: https://www.sciencedirect.com/science/article/abs/pii/S022352342500011X
|
|
193. Rong, J. and Liang, S. H. “Novel 5,6-fused and 6,6-fused bicyclic compounds as 15-prostaglandin dehydrogenase modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 3, 366–367. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00010 |
|
192. Hu, Q.-L. and Liang, S. H. “Novel Cyclic Peptides Inhibiting Tumor Necrosis Factor Receptor 1 Activity”, ACS Medicinal Chemistry Letters, 2025, 16, 3, 363–365. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00011 |
|
191. Zhao, T. and Liang, S. H. “Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators”, ACS Medicinal Chemistry Letters, 2025, 16, 361-362. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00012 |
|
190. Xin, Z. and Liang, S. H. “Hydroquinazoline Derivatives as Novel Natriuretic Peptide Receptor 1 (NPR1) Activators”, ACS Medicinal Chemistry Letters, 2025, 16, 358-360. Link: https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00013 |
|
189. Song, Z. and Liang, S. H. “Identification of Phosphodiesterase-7 Inhibitors with Spiro[[1,3]Oxazolo[5,4-f]Quinazoline-9,1′-Cyclohexan]-7-One Scaffold for the Treatment of Chronic Fatigue”, ACS Medicinal Chemistry Letters, 2025, 16, 356–357. https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00001 |
|
188. Li, Y. and Liang, S. H. “Novel Piperazine Derivatives as Selective Antagonists of GluN2B-containing NMDARs under Acidic pH Conditions”, ACS Medicinal Chemistry Letters, 2025, 16, 354-355. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.5c00002 |
|
187. Tan, Z.; Nie, B.; Wu, H.; Li, B.; Shang, J.; Zhang, T.; Xiao, Z.; Dong, C.; Zeng, C.; Wu, B.; Hou, L.; Guo, B.; Cheng, Y.; Gong, J.; Ye, W.; Xu, L.; Li, Y.; Li, X.; Liang, S. H.; Shan, B.; Xu, H.; Wang, L. “Brain development during the lifespan of cynomolgus monkeys”, NeuroImage, 2025, 305, 120952. Link: https://pubmed.ncbi.nlm.nih.gov/39662788/
|
|
186. Hu, Q.-L. and Liang, S. H. “Cyclic Peptides Targeting Granzyme B: Potential Applications as PET Imaging Agents”, ACS Medicinal Chemistry Letters, 2025, 16, 180-181. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00608 |
|
185. Zhao, T. and Liang, S. H. “Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer”, ACS Medicinal Chemistry Letters, 2025, 16, 178-179. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00609 |
|
184. Li, Y. and Liang, S. H. “Novel Heterocyclic Piperazine Amide Derivatives as Alpha-synuclein PET Ligands for Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, 16, 184-185. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00606 |
|
183. Song, Z. and Liang, S. H. “Imaging Alpha-synuclein with Novel 5H-Imidazo[1,5-b][1,2,4]triazole Radioligands for the Diagnosis of Parkinson’s Disease”, ACS Medicinal Chemistry Letters, 2025, 2025, 16, 182-183. Link: https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.4c00607 |
|
182. Song, Z.; Li, Y.; Dahl, K.; Chaudhary, A.; Sun, Z.; Zhou, X.; Chen, J.; Gao, Y.; Rong, J.; Zhao, C.; Patel, J. S.; Collier, L.; Ran, C.; Zhai, C.; Zhang, L.; Haider, A.; Mühlfenzl, K. S.; Yuan, H.; Elmore, C. S.; Schou, M. and Liang, S. H. “Discovery of 18F-Labeled AZD5213 Derivatives as Novel Positron Emission Tomography (PET) Radioligands Targeting Histamine Subtype-3 Receptor”, ChemBioChem, 2025-02, Vol.26 (5), p.e202400655-n/a. Link: https://pubmed.ncbi.nlm.nih.gov/39303145/
|
|
181. Liao, K.; Chen, J.; Ma, J.; Dong, C.; Bi, C.; Gao, Y.; Jiang, Y.; Wang, T.; Wei, H.; Hou, L.; Hu, J.; Wei, J.; Zeng, C.; Li, Y.; Yan, S.; Xu, H.; Liang, S. H. and Wang, L. “Preclinical characterization of [18F]D2-LW223: an improved metabolically stable PET tracer for imaging the translocator protein 18 kDa (TSPO) in neuroinflammatory rodent models and non-human primates”, Acta Pharmacologica Sinica, 2025, 46, 393–403. Link: https://doi.org/10.1038/s41401-024-01375-9
|
